OKYO Pharma (OKYO) Stock Price, News & Analysis

Company Overview

Okyo Pharma Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for inflammatory and fibrotic diseases. The company’s pipeline is built on proprietary Fc-fusion technology designed to modulate immune responses associated with conditions such as diabetic nephropathy and chronic graft-versus-host disease. Okyo Pharma seeks to address significant unmet medical needs by targeting key cytokine pathways involved in tissue inflammation and fibrosis.

Okyo Pharma’s lead product candidate, OK-101, is an Fc-fusion protein in Phase 2 development for the treatment of diabetic kidney disease. The company’s second program, OK-202, is advancing in preclinical studies for chronic graft-versus-host disease, with plans to expand into other fibrotic indications. These programs leverage the company’s expertise in biologics engineering to deliver enhanced therapeutic profiles, including improved half-life and tissue targeting.

Founded through a combination of biotechnology collaborations and strategic financing, Okyo Pharma completed its initial public offering on the NASDAQ under the ticker symbol OKYO. Headquartered in the United States, the company has established research partnerships across North America and Europe to support its clinical development efforts. Leadership is headed by Chief Executive Officer Thomas Baum, Ph.D., who brings extensive experience in biologics development and regulatory strategy.

Key Stats

• Today's Range: $1.64 to $1.69
• 50-Day Range: $1.37 to $1.75
• 52-Week Range: $1.34 to $3.35
• Volume: 25,799 shs
• Average Volume: 175,816 shs
• Market Capitalization: $68.14 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $5.67
• Consensus Rating: Hold

OKYO Pharma Stock Analysis - MarketRank™

OKYO Pharma scored higher than 35% of companies evaluated by MarketBeat, and ranked 714th out of 894 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Hold

Consensus Rating

OKYO Pharma has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on no strong buy ratings, 3 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

OKYO Pharma has a consensus price target of $5.67, representing about 237.3% upside from its current price of $1.68.

Amount of Analyst Coverage

OKYO Pharma has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for OKYO Pharma are expected to decrease in the coming year, from ($0.22) to ($0.52) per share.

Price to Book Value per Share Ratio

OKYO Pharma has a P/B Ratio of 5.60. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.17% of the float of OKYO Pharma has been sold short.

Short Interest Ratio / Days to Cover

OKYO Pharma has a short interest ratio ("days to cover") of 0.22, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in OKYO Pharma has recently increased by 29.28%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

OKYO Pharma does not currently pay a dividend.

Dividend Growth

OKYO Pharma does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 2 news articles for OKYO Pharma this week, compared to 2 articles on an average week.

MarketBeat Follows

1 people have added OKYO Pharma to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, OKYO Pharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

40.46% of the stock of OKYO Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

2.97% of the stock of OKYO Pharma is held by institutions.

Company Calendar

• Today: 8/02/2026
• Next Earnings (Estimated): 8/10/2026
• Fiscal Year End: 3/31/2027

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:OKYO
• CIK: 1849296
• Web: www.okyopharma.com
• Phone: 44-20-7495-2379
• Fax: N/A
• Employees: 7
• Year Founded: N/A

Price Target and Rating

• Average Price Target for OKYO Pharma: $5.67
• High Price Target: $7.00
• Low Price Target: $5.00
• Potential Upside/Downside: +237.3%
• Consensus Rating: Hold
• Rating Score (0-4): 2.40
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.43
• Quick Ratio: 2.43

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.30 per share
• Price / Book: 5.60

Miscellaneous

• Outstanding Shares: 40,560,000
• Free Float: 24,146,000
• Market Cap: $68.14 million
• Optionable: Not Optionable
• Beta: 0.04